ImmunityBio, Inc. — Director's Dealing 2023

Jan 5, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2022-12-31

Reporting Person: Adcock Richard (Director, CEO & President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-31	Common Stock	M	8620	—	Acquired	148714	Direct
2022-12-31	Common Stock	F	4273	$5.07	Disposed	144441	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-12-31	Restricted Stock Units	$	M	8620	Disposed		Common Stock (8620.0)	Direct

Footnotes

F1: On December 31, 2022, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 30, 2022 was the settlement price used to calculate the shares withheld.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F3: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.